Teon Therapeutics, Inc.
Teon Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of oral, GPCR-targeted small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways in difficult-to-treat cancers. Their science is backed by a track record of success and passion to deliver improved options for patients, aiming to transform the treatment landscape with novel therapies targeting unexploited metabolic pathways.
Industries
Nr. of Employees
small (1-50)
Teon Therapeutics, Inc.
555 Twin Dolphin Dr, Suite 120, Redwood City, CA 94065
Patents
Products
Oral CB2 receptor antagonist (clinical candidate)
An orally administered, selective antagonist of the peripheral cannabinoid CB2 receptor developed as an immune‑modulating small molecule to enhance T cell and NK cell activity, increase immune cell tumor infiltration, and modulate the tumor microenvironment; evaluated clinically in Phase 1/2 trials.
Oral A2B adenosine receptor antagonist (clinical candidate)
An orally administered small‑molecule antagonist selective for the A2B adenosine receptor aimed at reducing adenosine‑mediated immune suppression in the tumor microenvironment; progressed into clinical evaluation.
MCT4 (lactate transport) inhibitor (preclinical)
Preclinical small‑molecule program targeting lactate transport to alter tumor metabolism and the immunosuppressive microenvironment; positioned for early partner evaluation.
CD73 enzyme inhibitor (preclinical)
Preclinical program targeting CD73 enzymatic activity to reduce adenosine generation in the tumor microenvironment and alleviate immune suppression.
Oral CB2 receptor antagonist (clinical candidate)
An orally administered, selective antagonist of the peripheral cannabinoid CB2 receptor developed as an immune‑modulating small molecule to enhance T cell and NK cell activity, increase immune cell tumor infiltration, and modulate the tumor microenvironment; evaluated clinically in Phase 1/2 trials.
Oral A2B adenosine receptor antagonist (clinical candidate)
An orally administered small‑molecule antagonist selective for the A2B adenosine receptor aimed at reducing adenosine‑mediated immune suppression in the tumor microenvironment; progressed into clinical evaluation.
MCT4 (lactate transport) inhibitor (preclinical)
Preclinical small‑molecule program targeting lactate transport to alter tumor metabolism and the immunosuppressive microenvironment; positioned for early partner evaluation.
CD73 enzyme inhibitor (preclinical)
Preclinical program targeting CD73 enzymatic activity to reduce adenosine generation in the tumor microenvironment and alleviate immune suppression.
Services
Structuring and executing collaboration agreements to run combination arms or sponsored clinical studies with external pharmaceutical and academic partners.
Strategic alliances with investors, non‑profit organizations and development partners to sponsor and advance clinical development programs.
Structuring and executing collaboration agreements to run combination arms or sponsored clinical studies with external pharmaceutical and academic partners.
Strategic alliances with investors, non‑profit organizations and development partners to sponsor and advance clinical development programs.
Expertise Areas
- Phase 1/2 clinical development and management
- GPCR small‑molecule discovery and therapeutic design
- Medicinal chemistry and lead optimization
- Tumor microenvironment and immuno‑oncology
Key Technologies
- GPCR‑targeted small‑molecule modulators
- CB2 receptor antagonists
- A2B adenosine receptor antagonists
- MCT4 (lactate transport) inhibitors
News & Updates
Teon announced that the first patient has been treated in its Phase 1/2 clinical trial evaluating TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors and stimulating NK cell tumor killing.
Teon announced that the FDA has accepted its IND application for TT-816, a first-in-class, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor, with plans to initiate Phase 1/2 clinical trial in Q3 2022.
Teon completed its Series A financing round, raising $30 million to advance its pipeline and clinical programs.
Teon announced that the first patient has been treated in its Phase 1/2 clinical trial evaluating TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors and stimulating NK cell tumor killing.
Teon announced that the FDA has accepted its IND application for TT-816, a first-in-class, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor, with plans to initiate Phase 1/2 clinical trial in Q3 2022.
Teon completed its Series A financing round, raising $30 million to advance its pipeline and clinical programs.